Biotech News

MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN

MacroGenics (MGNX)MacroGenics2026-10-23 13:15 ESTClinical readout

Durable responses observed across multiple tumor types during dose escalation MGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated SCCHN patients MGC026 demonstrated manageable safety and tolerability profile with no

Related news

MGNXMacroGenics2026-10-15 20:05 EST

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

BNTXBioNTech2026-10-22 10:45 EST

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

PRLDPrelude Therapeutics2026-10-13 11:01 EST

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

INBXInhibrx2026-09-08 11:30 EST

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

GSKGSK plc2026-10-23 23:00 EST

GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer

RVMDRevolution Medicines2026-10-15 13:46 EST

Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

BNTXBioNTech2026-10-13 10:45 EST

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

IDYAIDEAYA Biosciences2026-09-09 10:00 EST

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

View all latest news

MacroGenics

Antibody Engineering Company MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates. ADC Portfolio MGC026 targets B7-H3 and is in Phase 1 dose expansion, while MGC028 targets ADAM9 and is in Phase 1 dose escalation across advanced solid...

Recent company news

MGNXMacroGenics2026-10-23 13:15 EST

MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN

MGNXMacroGenics2026-10-15 20:05 EST

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

MGNXMacroGenics2026-08-11 20:05 EST

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

Stock data

Close: 3.63 USD
Market cap: 257.43M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States